Progress in the study of parvovirus entry pathway

Shi, Jiuming; Pei, Yifeng; Yu, Qian; Dong, Hao

doi:10.1186/s12985-023-02016-z

Cited by 2 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By hijacking aberrant signalling pathways such as the Ras pathway, Protoparvovirus H-1PV facilitates its replication and spread within the tumour microenvironment, selectively killing cancer cells while sparing normal cells ( 40 ).…”

Section: Types Of Viruses Used In Oncolytic Trialsmentioning

confidence: 99%

New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy

Chowaniec,

Ślubowska,

Mroczek

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Oncolytic virus (OV) therapy has emerged as a promising frontier in cancer treatment, especially for solid tumours. While immunotherapies like immune checkpoint inhibitors and CAR-T cells have demonstrated impressive results, their limitations in inducing complete tumour regression have spurred researchers to explore new approaches targeting tumours resistant to current immunotherapies. OVs, both natural and genetically engineered, selectively replicate within cancer cells, inducing their lysis while sparing normal tissues. Recent advancements in clinical research and genetic engineering have enabled the development of targeted viruses that modify the tumour microenvironment, triggering anti-tumour immune responses and exhibiting synergistic effects with other cancer therapies. Several OVs have been studied for breast cancer treatment, including adenovirus, protoparvovirus, vaccinia virus, reovirus, and herpes simplex virus type I (HSV-1). These viruses have been modified or engineered to enhance their tumour-selective replication, reduce toxicity, and improve oncolytic properties.Newer generations of OVs, such as Oncoviron and Delta-24-RGD adenovirus, exhibit heightened replication selectivity and enhanced anticancer effects, particularly in breast cancer models. Clinical trials have explored the efficacy and safety of various OVs in treating different cancers, including melanoma, nasopharyngeal carcinoma, head and neck cancer, and gynecologic malignancies. Notably, Talimogene laherparepvec (T-VEC) and Oncorine have. been approved for advanced melanoma and nasopharyngeal carcinoma, respectively. However, adverse effects have been reported in some cases, including flu-like symptoms and rare instances of severe complications such as fistula formation. Although no OV has been approved specifically for breast cancer treatment, ongoing preclinical clinical trials focus on four groups of viruses. While mild adverse effects like low-grade fever and nausea have been observed, the effectiveness of OV monotherapy in breast cancer remains insufficient. Combination strategies integrating OVs with chemotherapy, radiotherapy, or immunotherapy, show promise in improving therapeutic outcomes. Oncolytic virus therapy holds substantial potential in breast cancer treatment, demonstrating safety in trials. Multi-approach strategies combining OVs with conventional therapies exhibit more promising therapeutic effects than monotherapy, signalling a hopeful future for OV-based breast cancer treatments.

show abstract

Section: Types Of Viruses Used In Oncolytic Trialsmentioning

confidence: 99%

New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy

Chowaniec,

Ślubowska,

Mroczek

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

For better or worse: crosstalk of parvovirus and host DNA damage response

Chen,

Liu,

Yang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Parvoviruses are a group of non-enveloped DNA viruses that have a broad spectrum of natural infections, making them important in public health. NS1 is the largest and most complex non-structural protein in the parvovirus genome, which is indispensable in the life cycle of parvovirus and is closely related to viral replication, induction of host cell apoptosis, cycle arrest, DNA damage response (DDR), and other processes. Parvovirus activates and utilizes the DDR pathway to promote viral replication through NS1, thereby increasing pathogenicity to the host cells. Here, we review the latest progress of parvovirus in regulating host cell DDR during the parvovirus lifecycle and discuss the potential of cellular consequences of regulating the DDR pathway, targeting to provide the theoretical basis for further elucidation of the pathogenesis of parvovirus and development of new antiviral drugs.

show abstract

Progress in the study of parvovirus entry pathway

Cited by 2 publications

References 48 publications

New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy

New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy

For better or worse: crosstalk of parvovirus and host DNA damage response

Contact Info

Product

Resources

About